Valley National Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Valley National Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-422	Closed	-$2K	–	907
2021 Q3	$2K	Hold	422	–	–	﹤0.01%	748
2021 Q2	$2K	Hold	422	–	–	﹤0.01%	766
2021 Q1	$3K	Hold	422	–	–	﹤0.01%	677
2020 Q4	$2K	Hold	422	–	–	﹤0.01%	676
2020 Q3	$2K	Hold	422	–	–	﹤0.01%	639
2020 Q2	$2K	Hold	422	–	–	﹤0.01%	637
2020 Q1	$1K	Buy	+422	New	+$1.79K	﹤0.01%	670
2019 Q4	–	Sell	-422	Closed	-$1K	–	747
2019 Q3	$1K	Hold	422	–	–	﹤0.01%	702
2019 Q2	$3K	Buy	+422	New	+$4.32K	﹤0.01%	591

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Valley National Advisers's AMRX Position: Q4 2021 in Review

Valley National Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q4 2021, closing a stake of 422 shares — an estimated $2K sold.

Valley National Advisers first reported a position in AMRX in Q2 2019 and held it in 9 quarters. The position peaked at $3K in Q1 2021. 154 funds tracked by Wall St. Rank hold AMRX as of Q4 2021.

Valley National Advisers reported no remaining Amneal Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Valley National Advisers sold 422 Amneal Pharmaceuticals shares in Q4 2021, an estimated $2K.
Valley National Advisers first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 9 quarters.
Valley National Advisers's Amneal Pharmaceuticals position peaked at $3K in Q1 2021.
154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2021.

Based on Valley National Advisers's 13F filing for Q4 2021, filed 11 Feb 2022.